DK2782602T3 - Nukleotid DIMS0-150 til anvendelse i behandling af kronisk aktiv ulcerøs colitis - Google Patents

Nukleotid DIMS0-150 til anvendelse i behandling af kronisk aktiv ulcerøs colitis

Info

Publication number
DK2782602T3
DK2782602T3 DK12790904.2T DK12790904T DK2782602T3 DK 2782602 T3 DK2782602 T3 DK 2782602T3 DK 12790904 T DK12790904 T DK 12790904T DK 2782602 T3 DK2782602 T3 DK 2782602T3
Authority
DK
Denmark
Prior art keywords
dims0
nucleotide
treatment
ulcerative colitis
chronic active
Prior art date
Application number
DK12790904.2T
Other languages
Danish (da)
English (en)
Inventor
Charlotte Admyre
Arezou Zargari
Stein Oliver Von
Stein Petra Von
Original Assignee
Index Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Index Pharmaceuticals Ab filed Critical Index Pharmaceuticals Ab
Application granted granted Critical
Publication of DK2782602T3 publication Critical patent/DK2782602T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/17Immunomodulatory nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/31Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK12790904.2T 2011-11-25 2012-11-23 Nukleotid DIMS0-150 til anvendelse i behandling af kronisk aktiv ulcerøs colitis DK2782602T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11190826.5A EP2596806A1 (en) 2011-11-25 2011-11-25 Method for prevention of colectomy
US201261595230P 2012-02-06 2012-02-06
PCT/EP2012/073501 WO2013076262A1 (en) 2011-11-25 2012-11-23 Method for prevention of colectomy

Publications (1)

Publication Number Publication Date
DK2782602T3 true DK2782602T3 (da) 2019-09-30

Family

ID=45094516

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12790904.2T DK2782602T3 (da) 2011-11-25 2012-11-23 Nukleotid DIMS0-150 til anvendelse i behandling af kronisk aktiv ulcerøs colitis

Country Status (16)

Country Link
US (3) US9492516B2 (cg-RX-API-DMAC7.html)
EP (3) EP2596806A1 (cg-RX-API-DMAC7.html)
JP (2) JP6193248B2 (cg-RX-API-DMAC7.html)
CA (1) CA2892203C (cg-RX-API-DMAC7.html)
CY (1) CY1122089T1 (cg-RX-API-DMAC7.html)
DK (1) DK2782602T3 (cg-RX-API-DMAC7.html)
ES (1) ES2745677T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20191723T1 (cg-RX-API-DMAC7.html)
HU (1) HUE046154T2 (cg-RX-API-DMAC7.html)
LT (1) LT2782602T (cg-RX-API-DMAC7.html)
PL (1) PL2782602T3 (cg-RX-API-DMAC7.html)
PT (1) PT2782602T (cg-RX-API-DMAC7.html)
RS (1) RS59358B1 (cg-RX-API-DMAC7.html)
SI (1) SI2782602T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900527T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013076262A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2881808C (en) * 2013-07-05 2021-08-17 Sony Corporation Transmission apparatus, transmission method, reception apparatus, and reception method
JP2019535839A (ja) 2016-11-29 2019-12-12 ピュアテック ヘルス エルエルシー 治療剤の送達のためのエクソソーム
BR112019021520A2 (pt) 2017-04-14 2020-08-04 Tollnine, Inc. oligonucleotídeo, composto, polinucleotídeo imunomodulador, composição, conjugado, método para modular um receptor, método de tratamento de um tumor, método de tratamento de câncer, método para tratar um tumor, método de prevenção de câncer, método para induzir uma resposta imune
GB201707501D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New therapy 2
GB201707503D0 (en) * 2017-05-10 2017-06-21 Index Pharmaceuticals Ab New Therapy 3
GB201807312D0 (en) * 2018-05-03 2018-06-20 Index Pharmaceuticals Ab Formulation
GB201818579D0 (en) * 2018-11-14 2018-12-26 Index Pharmaceuticals Ab New therapy
GB201912191D0 (en) * 2019-08-24 2019-10-09 Index Pharmaceuticals Ab New therapy
EP4147688A1 (en) * 2021-09-09 2023-03-15 InDex Pharmaceuticals AB Enema formulation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
JP4359654B2 (ja) 1996-01-30 2009-11-04 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 抗原特異的免疫応答を生起させる遺伝子発現ベクターおよびその使用方法
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US6339068B1 (en) 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
US6809193B2 (en) * 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
AU2006205571B2 (en) 2005-01-13 2012-03-22 Progenika Biopharma, S.A. Methods and products for in vitro genotyping
JPWO2006132204A1 (ja) 2005-06-06 2009-01-08 アンジェスMg株式会社 転写因子デコイ
EP1904077B1 (en) 2005-07-01 2009-08-12 Index Pharmaceuticals AB Modulating responsiveness to steroids
ES2450593T3 (es) 2005-07-01 2014-03-25 Index Pharmaceuticals Ab Método inmunoestimulante
US8637479B2 (en) 2008-11-04 2014-01-28 Index Pharmaceuticals Ab Compounds and methods for the treatment of inflammatory diseases of the CNS

Also Published As

Publication number Publication date
JP2017061508A (ja) 2017-03-30
CA2892203C (en) 2021-11-16
RS59358B1 (sr) 2019-11-29
SMT201900527T1 (it) 2019-11-13
PL2782602T3 (pl) 2019-12-31
LT2782602T (lt) 2019-10-10
CA2892203A1 (en) 2013-05-30
US20150004187A1 (en) 2015-01-01
JP6318221B2 (ja) 2018-04-25
HRP20191723T1 (hr) 2019-12-13
US9795627B2 (en) 2017-10-24
US9492516B2 (en) 2016-11-15
ES2745677T3 (es) 2020-03-03
WO2013076262A1 (en) 2013-05-30
US20170014442A1 (en) 2017-01-19
EP2782602B1 (en) 2019-06-26
JP6193248B2 (ja) 2017-09-06
EP2596806A1 (en) 2013-05-29
SI2782602T1 (sl) 2019-11-29
HUE046154T2 (hu) 2020-02-28
JP2015504438A (ja) 2015-02-12
EP2782602A1 (en) 2014-10-01
US20180015117A1 (en) 2018-01-18
EP3556403A1 (en) 2019-10-23
CY1122089T1 (el) 2020-11-25
PT2782602T (pt) 2019-10-14

Similar Documents

Publication Publication Date Title
DK2782602T3 (da) Nukleotid DIMS0-150 til anvendelse i behandling af kronisk aktiv ulcerøs colitis
EP2785234A4 (en) SURFACE CLEANING DEVICE
EP2823392A4 (en) SPECULATIVE PROCESSING AT APPLICATION LEVEL
DK2707029T3 (da) Fremgangsmåder til at behandle eller forebygge kolesterolrelaterede sygdomme
HRP20180237T1 (hr) Metode za liječenje hcv-a
PL2673237T3 (pl) Zastosowanie krzemianu cyrkonu do leczenia hiperkaliemii
IL231351A0 (en) Amino-substituted imidazopyridazines
LT2701773T (lt) Injekcinio švirkšto dozės kreiptuvai
EP2661169A4 (en) SELF-DRIVEN FUSIONING
DK3040336T3 (da) Forbindelser til brug i behandling af TYK2 Kinase-medierede tilstande
EP2688378A4 (en) Substrate unit
DK2773648T3 (da) Farmaceutiske forbindelser til anvendelse i behandlingen af clostridium difficile-infektion
HUE063599T2 (hu) Eljárások ödémás fibroszklerotikus pannikulopátia kezelésére vagy csökkentésére
DK2489413T5 (da) Behandlingsapparat
HUE046508T2 (hu) Orvepitant krónikus viszketés kezelésére
EP2780012A4 (en) Methods of treatment with deferiprone
IL229081A0 (en) Isoxazolines as therapeutic agents
GB201110781D0 (en) Liquid treatment systems
FI20116093L (fi) Vettä käsittelevä laitos
IL237150A0 (en) Treatment regimens
IL228729A0 (en) Treatment regimens
HRP20180011T1 (hr) Spojevi za uporabu u liječenju filariaza
DK2694056T3 (da) Terapeutisk behandling
HUE040153T2 (hu) Transzdermális vénás hozzáférést gátló oldatok
HRP20150141T1 (xx) Upotreba nifuratela u lijeäśenju infekcija uzrokovanih klostridijima